Development of small-molecule therapeutics targeting RNA.
Our company is a R&D driven biotechnology firm specializing in therapeutic and diagnostic seeds for pancreatic cancer. We are developing antibodies that target pancreatic cancer stem cells and products utilizing unique antibodies derived from pancreatic cancer patients. Dedicated to bringing early diagnostic tools and effective treatments for pancreatic cancer to patients as quickly as possible, our goal is to ensure that our drug seeds and innovative technologies make a significant contribution to the treatment and early detection of pancreatic cancer.
We provide a system that analyzes medical images using AI and outputs musculoskeletal data.
At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
An Osaka-based startup that designs and develops the edge AI processor “AiOnIc®” with low power consumption and a proprietary architecture (aIPE), providing integrated LSI and software solutions.